The invention provides a labeling composition for an intraocular tissue of a living individual, which specifically labels the intraocular tissue without need of an invasive operation such as exposure of an ocular tissue or injection of a staining agent into the ocular tissue or a nerve tissue linking to the ocular tissue, a method of noninvasively labeling an intraocular tissue of a living individual, and a screening method using the labeling composition for the intraocular tissues. The composition contains a compound capable of labeling at least a photoreceptor cell layer of a retina, wherein the compound is a staining compound having a particular structure as a partial structure thereof.

A lithium battery includes a cathode including a cathode active material, an anode including an anode active material, and an organic electrolytic solution between the cathode and the anode, wherein the organic electrolytic solution includes a first lithium salt, a second lithium salt, an organic solvent, and a bicyclic sulfate-based compound represented by Formula 1 below: ##STR00001## wherein, in Formula 1, each of A.sub.1, A.sub.2, A.sub.3, and A.sub.4 is independently a covalent bond, a substituted or unsubstituted C.sub.1-C.sub.5 alkylene group, a carbonyl group, or a sulfinyl group, in which both A.sub.1 and A.sub.2 are not a covalent bond and both A.sub.3 and A.sub.4 are not a covalent bond. The second lithium salt includes at least one selected from LiCF.sub.3SO.sub.3, Li(CF.sub.3SO.sub.2).sub.2N, LiC.sub.4F.sub.9SO.sub.3, Li(FSO.sub.2).sub.2N, and LiN(C.sub.xF.sub.2x+1SO.sub.2)(C.sub.yF.sub.2y+1SO.sub.2) where 2≤x≤20 and 2≤y≤20.

A lithium battery includes a cathode including a cathode active material, an anode including an anode active material, and an organic electrolytic solution between the cathode and the anode, wherein the organic electrolytic solution includes a first lithium salt, a second lithium salt, an organic solvent, and a bicyclic sulfate-based compound represented by Formula 1 below: ##STR00001## wherein, in Formula 1, each of A.sub.1, A.sub.2, A.sub.3, and A.sub.4 is independently a covalent bond, a substituted or unsubstituted C.sub.1-C.sub.5 alkylene group, a carbonyl group, or a sulfinyl group, in which both A.sub.1 and A.sub.2 are not a covalent bond and both A.sub.3 and A.sub.4 are not a covalent bond. The second lithium salt includes at least one selected from LiCF.sub.3SO.sub.3, Li(CF.sub.3SO.sub.2).sub.2N, LiC.sub.4F.sub.9SO.sub.3, Li(FSO.sub.2).sub.2N, and LiN(C.sub.xF.sub.2x+1SO.sub.2)(C.sub.yF.sub.2y+1SO.sub.2) where 2≤x≤20 and 2≤y≤20.

A photochromic compound of the present invention comprises at least two monovalent photochromic basic structure groups PC including a T-type photochromic moiety, the photochromic basic structure groups being bonded to an organic group having a non-SO aromatic ring containing neither a sulfur atom nor an oxygen atom.

A photochromic compound of the present invention comprises at least two monovalent photochromic basic structure groups PC including a T-type photochromic moiety, the photochromic basic structure groups being bonded to an organic group having a non-SO aromatic ring containing neither a sulfur atom nor an oxygen atom.

Compounds of the formula I ##STR00001##
in which X.sup.1, X.sup.2, X.sup.3, X.sup.4, R.sup.1, R.sup.2, R.sup.3, Q and Y have the meanings indicated in Claim 1,
are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Compounds of the formula I ##STR00001##
in which X.sup.1, X.sup.2, X.sup.3, X.sup.4, R.sup.1, R.sup.2, R.sup.3, Q and Y have the meanings indicated in Claim 1,
are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

The present invention relates to novel compounds of formula (I) or formula (Ia)

##STR00001##

pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.

The present invention relates to novel compounds of formula (I) or formula (Ia)

##STR00001##

pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.

A chromene compound having at least one indenonaphthopyran moiety which has a group forming a spiro ring together with the 13-position carbon atom and further an oligomer chain group selected from a polyalkylene oxide oligomer chain group having at least three recurring units and a polyester oligomer chain group having at least three recurring units, represented by the following formula and having reduced matrix dependence: ##STR00001##
wherein R.sup.1 and R.sup.2 are each a group which may have an oligomer chain group, the ring Z bonded to the 13-position carbon atom of the chromene compound is a Spiro ring group, and R.sup.3 and R.sup.4 are each an aryl group or heteroaryl group which may have an oligomer chain group. Preferably, the chromene compound has at least one oligomer chain group in the molecule.